Dupont Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Dupont Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,616	Closed	-$83K	–	1471
2022 Q3	$83K	Buy	+8,616	New	+$99.4K	﹤0.01%	1092
2021 Q1	–	Sell	-4,869	Closed	-$226K	–	1612
2020 Q4	$226K	Hold	4,869	–	–	﹤0.01%	1113
2020 Q3	$160K	Sell	4,869 -14,758	-75%	-$452K	﹤0.01%	1144
2020 Q2	$539K	Sell	19,627 -494	-2%	-$16.2K	0.01%	744
2020 Q1	$602K	Sell	20,121 -5,352	-21%	-$142K	0.01%	615
2019 Q4	$705K	Buy	+25,473	New	+$579K	0.02%	687
2019 Q2	–	Sell	-37,870	Closed	-$360K	–	1235
2019 Q1	$360K	Hold	37,870	–	–	0.01%	885
2018 Q4	$335K	Buy	37,870 +9,933	+36%	+$95.8K	0.01%	883
2018 Q3	$314K	Buy	+27,937	New	+$397K	0.01%	821

Other funds holding IOVA

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dupont Capital Management's IOVA Position: Q4 2022 in Review

Dupont Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 8,616 shares — an estimated $83K sold.

Dupont Capital Management first reported a position in IOVA in Q3 2018 and held it in 9 quarters. The position peaked at $705K in Q4 2019. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Dupont Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Dupont Capital Management sold 8,616 Iovance Biotherapeutics shares in Q4 2022, an estimated $83K.
Dupont Capital Management first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 9 quarters.
Dupont Capital Management's Iovance Biotherapeutics position peaked at $705K in Q4 2019.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.